Lineage Cell Therapeutics Inc (AMEX:LCTX) shares, rose in value on Thursday, February 13, with the stock price up by 6.86% to the previous day’s close as strong demand from buyers drove the stock to $0.69.
Actively observing the price movement in the last trading, the stock closed the session at $0.64. Referring to stock’s 52-week performance, its high was $1.61, and the low was $0.48. On the whole, LCTX has fluctuated by 24.55% over the past month.
With the market capitalization of Lineage Cell Therapeutics Inc currently standing at about $150.99 million, investors are eagerly awaiting this quarter’s results, scheduled for in March.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 8.25M, with a low estimate of 840k and a high estimate of 3.78M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.62M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that LCTX’s technical picture suggests that short-term indicators denote the stock is a Hold on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of LCTX currently trading nearly 6.84% and 17.27% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 57.09, while the 7-day volatility ratio is showing 7.11% which for the 30-day chart, stands at 8.74%. Furthermore, Lineage Cell Therapeutics Inc (LCTX)’s beta value is 1.27, and its average true range (ATR) is 0.06.
A comparison of Lineage Cell Therapeutics Inc (LCTX) with its peers suggests the former has fared considerably weaker in the market. LCTX showed an intraday change of 6.86% in last session, and over the past year, it shrunk by -36.57%%.
Data on historical trading for Lineage Cell Therapeutics Inc (AMEX:LCTX) indicates that the trading volumes over the past 3 months, they’ve averaged 2.69 million. According to company’s latest data on outstanding shares, there are 220.42 million shares outstanding.
Nearly 0.43% of Lineage Cell Therapeutics Inc’s shares belong to company insiders and institutional investors own 48.27% of the company’s shares. The stock has risen by 36.32% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LCTX stock heading into the next quarter.
